Company Overview and News

2
With a Strong Focus on ALS Patients, Mitsubishi Tanabe Pharma America Works to Increase Access an...

2018-06-01 biospace
It has been one year since Mitsubishi Tanabe Pharma America’s (MTPA) Radicava was approved as the first treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years. Since its approval, MTPA has been aggressive in its efforts to get the medication in the hands of ALS patients. The drug officially rolled out to U.S. patients in August 2017.
MTZXF MTZPY 4508

2
Dyadic International's (DYAI) CEO Mark Emalfarb on Q1 2018 Results - Earnings Call Transcript

2018-05-14 seekingalpha
Good afternoon, ladies and gentlemen, and thank you for holding. Welcome to Dyadic International's First Quarter 2018 Financial Results Conference Call. Now, all participants are in a listen-only mode. My name is Dana and I'll be your conference coordinator today. As a reminder, please note that this call is being recorded.
MTZXF MTZPY DYAI 4508

15
Regeneron Pharmaceuticals (REGN) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to the Regeneron Pharmaceuticals First Quarter 2018 Earnings Conference Call. My name is Jason and I will be your operator. At this time all participants will be in a listen-only mode. Later, we will have a question-and-answer session. Also, please note this conference is being recorded.
MTZXF REGN MTZPY GCVRZ SAN SNYNF 4508 SNY

2
The Drug Committee of Ministry of Health, Labour and Welfare in Japan has accepted a 2-year extension of market exclusivity of Lexapro®

2018-04-27 globenewswire
Valby, Denmark, 27 April 2018 - H. Lundbeck A/S (Lundbeck) today announced that Lexapro® (escitalopram oxalate), which is distributed by Mochida Pharmaceutical Co., Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) in Japan, is expected to receive a final confirmation of the extension of the eight-year market exclusivity by the Japanese Ministry of Health, Labour and Welfare (MHLW).
MTZXF MTZPY 4508

2
Det japanske Sundheds-, arbejds- og socialministerium (MHLW) accepterer en forlængelse af markedseksklusivitet på to år for Lexapro®

2018-04-27 globenewswire
Valby, Danmark, 27. april 2018 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Lexapro® (escitalopram oxalat), som markedsføres af Mochida Pharmaceutical Co., Ltd. (Mochida) og Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) i Japan, forventes at modtage endelig bekræftelse på en forlængelse af den otteårige markedseksklusivitet af det japanske Sundheds-, arbejds- og socialministerium (Ministry of Health, Labour and Welfare – herefter MHLW).
MTZXF MTZPY 4508

2
Neuraltus Weighs Future of Lead Candidate NP001 After Failure in Phase II ALS Trial

2018-04-26 genengnews
Neuraltus Pharmaceuticals said today it is weighing if, and how, it plans to continue developing its lead candidate NP001 after it failed a Phase II confirmatory study in ALS patients with elevated levels of systemic inflammation—a review that makes the drug unlikely to be the third approved treatment for the disease any time soon, if ever.
MTZXF MTZPY 4508

2
Amgen Backs Launch of Golden Ticket Winning ALS Company QurAlis

2018-04-05 biospace
After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).
MTZXF MTZPY 4508

2
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2017 Results - Earnings Call Transcript

2018-03-28 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for holding. Welcome to Dyadic International’s 2017 Year-End Financial Results Conference Call. At this time all participants are in a listen-only mode. My name is Catherine, I will be your conference coordinator for today. As a reminder, please note that this call is being recorded.
MTZXF MTZPY DYAI 4508

2
Dyadic International Announces 2017 Year End Results and Recent Developments

2018-03-27 globenewswire
JUPITER, Fla., March 27, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying our proprietary C1 gene expression platform to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced its financial results for the year ended December 31, 2017, and recent company developments.
MTZXF MTZPY DYAI 4508

14
Akebia Announces $85M Public Offering

2018-03-23 biospace
Cambridge, Massachusetts-based Akebia Therapeutics announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.
MTZXF MS.PRI MTZPY MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA 4508

11
VIVUS Reports Fourth Quarter 2017 Financial Results

2018-03-13 marketwired
CAMPBELL, CA--(Marketwired - March 13, 2018) - VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter and year ended December 31, 2017 and provided a business update.
VVUS MTZXF MTZPY 4508

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 006870984